Evidence map›Paper›PMID 30093715›Full record

ArticleThe pharmacogenomics journal2019

Cross-ethnicity tagging SNPs for HLA alleles associated with adverse drug reaction.

Michael Erlichster, Benjamin Goudey, Efstratios Skafidas, Patrick Kwan

Abstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Single Nucleotide Variants as Proxies forFrontiers in pharmacology · 2022
    Article
  2. Human Leukocyte Antigen (HLA) Testing in Pharmacogenomics.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michael ErlichsterCentre for Neural Engineering, University of Melbourne, Melbourne, Victoria, Australia. erm@student.unimelb.edu.au.
Benjamin GoudeyIBM Research - Australia, Carlton, Victoria, Australia.ORCID http://orcid.org/0000-0002-2318-985X
Efstratios SkafidasCentre for Neural Engineering, University of Melbourne, Melbourne, Victoria, Australia.
Patrick KwanCentre for Neural Engineering, University of Melbourne, Melbourne, Victoria, Australia.
The University of Melbourne · AUThe Royal Melbourne Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reduction of adverse drug reaction (ADR) incidence through screening of predisposing human leucocyte antigen (HLA) alleles is a promising approach for many widely used drugs. However, application of these associations has been limited by the cost burden of HLA genotyping. Use of single nucleotide polymorphisms (SNPs) that can approximate ('tag') HLA alleles of interest has been proposed as a cost-effective and simple alternative to conventional genotyping. However, most reported SNP tags have not been validated and there is concern regarding clinical utility of this approach due to tagging inconsistency across different populations. We assess the ability of 67 previously reported and 378 novel tagging SNPs, identified here in 5 HLA reference panels, to tag 15 ADR-associated HLA alleles in a panel of 955 ethnically diverse samples. Tags for 8 HLA alleles of interest were identified with 100% sensitivity and >95% specificity. These SNPs may act as a reliable genotyping approach for the routine screening of patients, without the need to account for patient ethnicity.

Indexed as

AllelesDrug-Related Side Effects and Adverse ReactionsEthnicityGenotypeHLA AntigensHumansPolymorphism, Single NucleotideHLA Antigens

Identifiers

PMID30093715
OpenAlexW2885887281

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.